在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。In this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short clip by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
在欧洲的真实世界数据源中，法国医疗保健数据库 SNDS 是最大、也可能是最全面的医疗保健数据资源，覆盖约 6500 万人的生活，超过 99% 的法国人口和约 10% 的欧洲人口。Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
Watch this presentation to learn • Overview of the SNDS and the key working practices to access the database and ongoing SNDS developments • Similarities and differences between SNDS and other claims databases • Strengths and opportunities for HTAs and market access in Europe through case studies • Stakeholder perspectives: current and potential benefits to … Continued
Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou Hemorrhagic cystitis (HC) caused by viral infections such as BK virus, cytomegalovirus, and/or adenovirus after allogeneic hematopoietic stem cell transplantation (allo-HCT) causes morbidity and mortality, affects quality of life, and poses a substantial burden to the health care system. At … Continued
BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the price of drugs nor how we pay for them: not patients, not the lawmakers who represent them, not physicians, not insurance payers and not drug developers. We are at a point where all stakeholders are fed up, and there’s (…)
Join us on 星期三, 四月 21, 2021, from12:00 PM – 2:00 PM EDT for Certara’s first annual Strategic Evidence & Value Communication Symposium. Across two panel discussions, a host of Certara and industry experts will debate and explore various best practices to ensure effective communication of product value, as well as the expanded use of Real World Evidence to accelerate market access decision-making.
